2.68

8.06% 0.20

After Hours: 2.65 -0.03 -1.12%

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $2.68, with a volume of 1.77M. It is up +8.06% in the last 24 hours and up +9.39% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Previous Close:

$2.48

Open:

$2.47

24h Volume:

1.77M

Relative Volume:

0.93

Market Cap:

$259.73M

Revenue:

$20.76M

Net Income/Loss:

$-132.49M

P/E Ratio:

-1.0037

EPS:

-2.67

Net Cash Flow:

$-108.55M

1W Performance:

+7.20%

1M Performance:

+9.39%

6M Performance:

+94.20%

1Y Performance:

-36.04%

1-Day Range:

$2.4501

$2.71

1-Week Range:

$2.2901

$2.71

52-Week Range:

$1.085

$5.10

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1136)

Industry

Biotechnology (634)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

110

Twitter

Next Earnings Date

2025-02-24

Latest SEC Filings

CCCC's Discussions on Twitter

Compare CCCC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CCCC C 4 Therapeutics Inc	2.68	240.35M	20.76M	-132.49M	-108.55M	-2.67
VRTX Vertex Pharmaceuticals Inc	432.17	109.05B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	784.61	82.75B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	445.12	56.78B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	917.63	56.52B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	204.51	44.58B	447.02M	-1.18B	-906.14M	-6.1812

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Initiated	Barclays	Overweight
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight
Sep-04-25	Initiated	Guggenheim	Buy
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Equal-Weight
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-13-23	Upgrade	Stifel	Hold → Buy
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

Nov 26, 2025

Mineralys Therapeutics reports inducement award under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Nov 26, 2025

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 26, 2025

Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss - Seeking Alpha

Nov 26, 2025

Nov 25, 2025

CCCC SEC FilingsC4 Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Nov 25, 2025

C4 Therapeutics (NASDAQ: CCCC) fireside chat at Evercore conference Dec. 3 2025 - Stock Titan

Nov 25, 2025

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - MarketScreener

Nov 25, 2025

Nov 22, 2025

C4 Therapeutics files $400M mixed shelf offering - MSN

Nov 22, 2025

Nov 21, 2025

C4 Therapeutics Inc files for mixed shelf of up to $400 millionSEC filing - MarketScreener

Nov 21, 2025

[S-3] C4 Therapeutics, Inc. Shelf Registration Statement | CCCC SEC FilingForm S-3 - Stock Titan

Nov 21, 2025

Nov 20, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Nov 20, 2025

How C4 Therapeutics Inc. stock responds to policy changes2025 Support & Resistance & Growth Focused Investment Plans - newser.com

Nov 20, 2025

Nov 19, 2025

Using economic indicators to assess C4 Therapeutics Inc. potentialWall Street Watch & Accurate Entry/Exit Alerts - newser.com

Nov 19, 2025

C4 Therapeutics Inc. stock trend forecastJuly 2025 Selloffs & Detailed Earnings Play Strategies - newser.com

Nov 19, 2025

Nov 18, 2025

Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Nov 18, 2025

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance

Nov 18, 2025

Nov 17, 2025

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 17, 2025

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Nov 17, 2025

Nov 16, 2025